DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Comparison of Ondansetron, Metoclopramide and Promethazine for the Treatment of Nausea and Vomiting in the Adult ED

Information source: Vanderbilt University
Information obtained from ClinicalTrials.gov on November 03, 2008
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Nausea

Intervention: ondansetron, metoclopramide, and promethazine (Drug)

Phase: N/A

Status: Recruiting

Sponsored by: Vanderbilt University

Official(s) and/or principal investigator(s):
Tyler W Barrett, MD, Principal Investigator, Affiliation: Vanderbilt University

Overall contact:
Fiona E. Remple, Phone: 615-936-8379, Email: fiona.remple@vanderbilt.edu

Summary

The purpose of this study is to compare the effectiveness of ondansetron, metoclopramide, and promethazine for the treatment of nausea in the adult emergency department population.

We hypothesize that a single intravenous dose of ondansetron is more effective in reducing nausea than a single IV dose of metoclopramide, promethazine or normal saline placebo in undifferentiated adult emergency department patients.

Clinical Details

Official title: A Randomized, Double Blind, and Placebo-Controlled Trial Comparing Ondansetron, Metoclopramide and Promethazine for the Treatment of Nausea and Vomiting in the Adult Emergency Department.

Study design: Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator), Single Group Assignment

Primary outcome: reduction in Visual Analog Scale (VAS) score for nausea

Eligibility

Minimum age: 18 Years. Maximum age: N/A. Gender(s): Both.

Criteria:

Inclusion Criteria:

- All patients age 18 or older who present to the ED with a complaint requiring

antiemetic treatment who do not meet the exclusion criteria.

Exclusion Criteria:

- Patients less than 18 years of age

- Unstable patients with SBP < 90

- Patients with a stated or documented allergy to any of the study medications

- Patients whose nausea rating if < 40 on the pretreatment VAS scale

- Patients who have received a commonly accepted antiemetic within the previous 24

hours

- Patients unwilling or unable to complete the assessment tool before and 30 minutes

after study drug dosing

Locations and Contacts

Fiona E. Remple, Phone: 615-936-8379, Email: fiona.remple@vanderbilt.edu

Vanderbilt University Medical Center, Nashville, Tennessee 37240, United States; Recruiting
Tyler W. Barrett, MD, Principal Investigator
Additional Information

Starting date: March 2007
Ending date: March 2009
Last updated: April 4, 2008

Page last updated: November 03, 2008

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2012